View Cart (0 items)


GlaxoSmithKline sets up $50 million fund to develop bioelectronic medicines

August 14, 2013
UK-based GlaxoSmithKline, one of the biggest pharmaceutical companies on the planet, wants to be a leader in the bioelectronic medicines space.
Read More

Chinese pharma probe spreads to two Danish drug makers

August 13, 2013
Western pharmaceutical companies are coming under increased scrutiny in China following the bribery accusations leveled last month against GlaxoSmithKline (GSK).
Read More

Generic drug patent settlements cut costs for health systems, study finds

July 11, 2013
The U.S. health system saved a total of $25.5 billion between 2005 and 2012 thanks to generic drugs being launched on the market before patent expirations as a result of patent settlements.
Read More

FDA bans production at New Jersey compound firm over sterility issues

July 9, 2013
The U.S. Food and Drug Administration (FDA) has taken action against New Jersey-based compounding pharmacy Med Prep Consulting, Inc. over concerns relating to the sterility of its production.
Read More

King Pharmaceuticals to pay $2.2 million over Clean Air Act violations

July 8, 2013
Tennessee-based King Pharmaceuticals, a subsidiary of Pfizer, Inc., will pay a $2.2. million penalty to resolve issues relating to allegations of Clean Air Act violations, the U.S. Environmental Protection Agency (EPA) announced.
Read More

Chinese pharma industry eyes international opportunities

July 1, 2013
Big Chinese pharmaceutical companies are no longer happy playing only in their local markets. Several of them are hoping to establish a notable presence on the U.S. market, mostly through partnerships with international industry giants.
Read More

U.S. pharmaceutical companies granted easier access to EU market

June 25, 2013
The United States is now considered a "listed country" by the European Commission, which means that U.S. companies don’t need an FDA export certificate before shipping certain pharmaceutical products to the European Union.
Read More

AstraZeneca to build new HQ, research center in Cambridge, UK

June 19, 2013
AstraZeneca is investing about £330 million ($515.6 million) in its new building, which will host a global R&D center.
Read More

Bill passed to fight counterfeit drugs

June 7, 2013
The United States has passed a bill intended to set up a national system for tracking pharmaceutical products through the supply chain to prevent counterfeit medicines from accessing the market.
Read More

FDA warns of counterfeit botox

May 7, 2013
The U.S. FDA has warned in recent days that fraudulent versions of Allergan's drug Botox are being distributed here in the U.S. The agency called for healthcare practitioners and the general public to exercise caution when dealing with the drug.
Read More